
    
      Induction treatment will be administered on a 21-day cycle for four/six cycles. Following the
      induction phase, participants will continue maintenance therapy with atezolizumab.
      Maintenance with atezolizumab will continue until disease progression (PD), unacceptable
      toxicity or loss of clinical benefit.
    
  